Dr. Mark G. Kris on the Future of Lung Cancer

Mark G. Kris, MD
Published: Tuesday, Nov 19, 2013

Mark G. Kris, MD, William and Joy Ruane Chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center, discusses the future of lung cancer treatment at the 8th Annual New York Lung Cancer Symposium®.

Kris says lung cancer treatment is evolving dramatically. As physicians understand more about the biology of lung cancer, Kris says, they will be able to identify new targets. Once targets are identified, it will be easier to find a treatment that combats the effects of the target.

The use of multimodality therapy is already being implemented, but Kris believes that it will be used more frequently in the future.

Mark G. Kris, MD, William and Joy Ruane Chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center, discusses the future of lung cancer treatment at the 8th Annual New York Lung Cancer Symposium®.

Kris says lung cancer treatment is evolving dramatically. As physicians understand more about the biology of lung cancer, Kris says, they will be able to identify new targets. Once targets are identified, it will be easier to find a treatment that combats the effects of the target.

The use of multimodality therapy is already being implemented, but Kris believes that it will be used more frequently in the future.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Updates in Novel Therapeutic Options for Lung Neuroendocrine TumorsMay 31, 20181.0
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Publication Bottom Border
Border Publication
x